(NASDAQ: LPTX) Leap Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Leap Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast LPTX's revenue for 2028 to be $1,154,546,717, with the lowest LPTX revenue forecast at $1,154,546,717, and the highest LPTX revenue forecast at $1,154,546,717. On average, 1 Wall Street analysts forecast LPTX's revenue for 2029 to be $1,633,960,628, with the lowest LPTX revenue forecast at $1,633,960,628, and the highest LPTX revenue forecast at $1,633,960,628.
In 2030, LPTX is forecast to generate $3,393,068,635 in revenue, with the lowest revenue forecast at $3,393,068,635 and the highest revenue forecast at $3,393,068,635.